4.5 Article

Efficacy of flash glucose monitoring in pregnant women with poorly controlled pregestational diabetes (FlashMom): A randomized pilot

期刊

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.numecd.2021.03.013

关键词

Flash glucose monitoring; Pregestational diabetes; Glucose control; HbA1c; Glycemic variability; Adverse pregnancy outcomes

资金

  1. Italian Society of Diabetology (SID) fellowship

向作者/读者索取更多资源

In women with pregestational diabetes, Flash Glucose Monitoring (FGM) and self-monitoring of blood glucose (SMBG) showed similar efficacy in glucose control during pregnancy, with FGM demonstrating additional advantages in terms of time below range (TBR) and glucose variability.
Background and aims: Good glycemic control is crucial to reduce the risk of adverse pregnancy outcomes. Our aim was to evaluate the efficacy of Flash Glucose Monitoring (FGM) on glucose control in women with pregestational diabetes. Methods and results: Forty women with inadequately controlled type 1 (T1D, n = 34) and type 2 (T2D, n = 6) diabetes at conception were randomly assigned to two arms: the Flash Glucose group (FG, n = 21) using FGM, and the control group (CG, n = 19) using self-monitoring of blood glucose (SMBG). Glycated hemoglobin (HbA1c, %), time in (TIR), below (TBR) and above (TAR) range, glucose variability as well as the occurrence of maternal and neonatal adverse outcomes, were evaluated. HbA1c decreased significantly (p < 0.01) and similarly (-0.65 +/- 0.7 vs.-0.67 +/- 0.8 for FG and CG, respectively; p = 0.89) in both groups during pregnancy. HbA1c reduction was positively associated with the number of daily FGM scans (p < 0.01). TBR (12.1 +/- 2.0% vs. 19.6 +/- 3.9%, p = 0.04) and the mean of the daily serum glucose difference (MODD) index (59.1 +/- 5.4 vs. 77.7 +/- 4.6, p = 0.02) were significantly lower in FG at second trimester. The rates of perinatal adverse outcomes were not different in the two studied groups. Conclusions: In women with pregestational diabetes, FGM and SMBG had similar efficacy on glucose control during pregnancy. FGM showed additional advantages in terms of TBR and glucose variability. Achievement of good metabolic results depended on the adequate use of glucose sensor. Registration: At ClinicalTrials.gov as NCT04666818 on December 14, 2020. (c) 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据